CONTEXT: There is substantial information that premenstrual dysphoric disorder (PMDD) is a clinically significant disorder with biological underpinnings that differ from other psychiatric disorders. However, data regarding the symptoms noted in DSM-IV and timing of their expression in the menstrual cycle have had little empirical support. OBJECTIVE: To provide evidence informing the definitional criteria for PMDD. DESIGN: Prospective surveys. SETTING: General community and clinical settings. PARTICIPANTS: Two cohorts that included a representative sample and a self-identified treatment-seeking cohort. Main Outcome Measure Daily ratings of perimenstrual symptoms and functioning. RESULTS: Mood and physical symptoms were most severe and were accompanied by impairment in the 4 days before through the first 2 days of menses for the self-identified group and in the 3 days before through the first 3 days of menses in the community sample. The most problematic symptoms endorsed were those listed in DSM-IV, but depressed mood was less frequent than other affective symptoms. In the combined sample, 4 or more symptoms was the optimal cutoff point for maximizing both sensitivity and specificity when predicting impairment. CONCLUSIONS: This is informative for DSM-5 in that the most symptomatic period typically includes the few days before through the first 3 days of menses rather than only the premenstrual phase. Further, we validated the salience of PMDD symptoms included in DSM-IV. Although the number of symptoms most associated with distress and impairment differed between the 2 cohorts, results from the combined cohort suggest that 4 symptoms are linked with impairment from PMDD symptoms.
CONTEXT: There is substantial information that premenstrual dysphoric disorder (PMDD) is a clinically significant disorder with biological underpinnings that differ from other psychiatric disorders. However, data regarding the symptoms noted in DSM-IV and timing of their expression in the menstrual cycle have had little empirical support. OBJECTIVE: To provide evidence informing the definitional criteria for PMDD. DESIGN: Prospective surveys. SETTING: General community and clinical settings. PARTICIPANTS: Two cohorts that included a representative sample and a self-identified treatment-seeking cohort. Main Outcome Measure Daily ratings of perimenstrual symptoms and functioning. RESULTS: Mood and physical symptoms were most severe and were accompanied by impairment in the 4 days before through the first 2 days of menses for the self-identified group and in the 3 days before through the first 3 days of menses in the community sample. The most problematic symptoms endorsed were those listed in DSM-IV, but depressed mood was less frequent than other affective symptoms. In the combined sample, 4 or more symptoms was the optimal cutoff point for maximizing both sensitivity and specificity when predicting impairment. CONCLUSIONS: This is informative for DSM-5 in that the most symptomatic period typically includes the few days before through the first 3 days of menses rather than only the premenstrual phase. Further, we validated the salience of PMDD symptoms included in DSM-IV. Although the number of symptoms most associated with distress and impairment differed between the 2 cohorts, results from the combined cohort suggest that 4 symptoms are linked with impairment from PMDD symptoms.
Authors: K A Yonkers; U Halbreich; E Freeman; C Brown; J Endicott; E Frank; B Parry; T Pearlstein; S Severino; A Stout; A Stone; W Harrison Journal: JAMA Date: 1997-09-24 Impact factor: 56.272
Authors: Kimberly A Yonkers; Candace Brown; Teri B Pearlstein; Marie Foegh; Carole Sampson-Landers; Andrea Rapkin Journal: Obstet Gynecol Date: 2005-09 Impact factor: 7.661
Authors: S W Hurt; P P Schnurr; S K Severino; E W Freeman; L H Gise; A Rivera-Tovar; J F Steege Journal: Am J Psychiatry Date: 1992-04 Impact factor: 18.112
Authors: M Steiner; S Steinberg; D Stewart; D Carter; C Berger; R Reid; D Grover; D Streiner Journal: N Engl J Med Date: 1995-06-08 Impact factor: 91.245
Authors: Namni Goel; Tracy L Bale; C Neill Epperson; Susan G Kornstein; Gloria R Leon; Lawrence A Palinkas; Jack W Stuster; David F Dinges Journal: J Womens Health (Larchmt) Date: 2014-09-26 Impact factor: 2.681
Authors: Kimberly A Yonkers; Brianna Cameron; Ralitza Gueorguieva; Margaret Altemus; Susan G Kornstein Journal: J Womens Health (Larchmt) Date: 2016-11-17 Impact factor: 2.681
Authors: Tory A Eisenlohr-Moul; Susan S Girdler; Katja M Schmalenberger; Danyelle N Dawson; Pallavi Surana; Jacqueline L Johnson; David R Rubinow Journal: Am J Psychiatry Date: 2016-08-13 Impact factor: 18.112